457 related articles for article (PubMed ID: 26917708)
1. Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model.
Song IH; Lee TS; Park YS; Lee JS; Lee BC; Moon BS; An GI; Lee HW; Kim KI; Lee YJ; Kang JH; Lim SM
J Nucl Med; 2016 Jul; 57(7):1105-11. PubMed ID: 26917708
[TBL] [Abstract][Full Text] [Related]
2. Immuno-PET imaging based radioimmunotherapy in head and neck squamous cell carcinoma model.
Song IH; Noh Y; Kwon J; Jung JH; Lee BC; Kim KI; Lee YJ; Kang JH; Rhee CS; Lee CH; Lee TS; Choi IJ
Oncotarget; 2017 Nov; 8(54):92090-92105. PubMed ID: 29190900
[TBL] [Abstract][Full Text] [Related]
3. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
4. Cumulated Activity Comparison of
Laffon E; Thumerel M; Jougon J; Marthan R
J Nucl Med; 2017 Jun; 58(6):888-890. PubMed ID: 28082435
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.
Niu G; Sun X; Cao Q; Courter D; Koong A; Le QT; Gambhir SS; Chen X
Clin Cancer Res; 2010 Apr; 16(7):2095-105. PubMed ID: 20215534
[TBL] [Abstract][Full Text] [Related]
6. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
7. Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model.
Song IH; Jeong MS; Hong HJ; Shin JI; Park YS; Woo SK; Moon BS; Kim KI; Lee YJ; Kang JH; Lee TS
Clin Cancer Res; 2019 Oct; 25(20):6148-6159. PubMed ID: 31337646
[TBL] [Abstract][Full Text] [Related]
8. PET Imaging Biomarkers of Anti-EGFR Immunotherapy in Esophageal Squamous Cell Carcinoma Models.
Lee TS; Song IH; Shin JI; Park YS; Kim JY; Kim KI; Lee YJ; Kang JH
Cells; 2018 Oct; 7(11):. PubMed ID: 30373221
[TBL] [Abstract][Full Text] [Related]
9. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
10. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
11. 177Lu-DO3A-HSA-Z EGFR:1907: characterization as a potential radiopharmaceutical for radionuclide therapy of EGFR-expressing head and neck carcinomas.
Hoppmann S; Qi S; Miao Z; Liu H; Jiang H; Cutler CS; Bao A; Cheng Z
J Biol Inorg Chem; 2012 Jun; 17(5):709-18. PubMed ID: 22418921
[TBL] [Abstract][Full Text] [Related]
12. Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer.
Yamaguchi A; Achmad A; Hanaoka H; Heryanto YD; Bhattarai A; Ratianto ; Khongorzul E; Shintawati R; Kartamihardja AAP; Kanai A; Sugo Y; S Ishioka N; Higuchi T; Tsushima Y
BMC Cancer; 2019 Oct; 19(1):1000. PubMed ID: 31651282
[TBL] [Abstract][Full Text] [Related]
13. The effect of chelator type on in vitro receptor binding and stability in 177Lu-labeled cetuximab and panitumumab.
Novy Z; Laznickova A; Mandikova J; Barta P; Laznicek M; Trejtnar F
J Labelled Comp Radiopharm; 2014 Jun; 57(7):448-52. PubMed ID: 24889367
[TBL] [Abstract][Full Text] [Related]
14. Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential.
Koi L; Bergmann R; Brüchner K; Pietzsch J; Pietzsch HJ; Krause M; Steinbach J; Zips D; Baumann M
Radiother Oncol; 2014 Feb; 110(2):362-9. PubMed ID: 24440046
[TBL] [Abstract][Full Text] [Related]
15. Imaging of Secreted Extracellular Periostin, an Important Marker of Invasion in the Tumor Microenvironment in Esophageal Cancer.
Heidari P; Esfahani SA; Turker NS; Wong G; Wang TC; Rustgi AK; Mahmood U
J Nucl Med; 2015 Aug; 56(8):1246-51. PubMed ID: 26069303
[TBL] [Abstract][Full Text] [Related]
16. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.
van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J
J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350
[TBL] [Abstract][Full Text] [Related]
17. Exploring pitfalls of
Striese F; Sihver W; Gao F; Bergmann R; Walther M; Pietzsch J; Steinbach J; Pietzsch HJ
Amino Acids; 2018 Oct; 50(10):1415-1431. PubMed ID: 30039310
[TBL] [Abstract][Full Text] [Related]
18. Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.
Hoeben BA; Molkenboer-Kuenen JD; Oyen WJ; Peeters WJ; Kaanders JH; Bussink J; Boerman OC
Int J Cancer; 2011 Aug; 129(4):870-8. PubMed ID: 20957635
[TBL] [Abstract][Full Text] [Related]
19. Novel Tumor Pretargeting System Based on Complementary l-Configured Oligonucleotides.
Schubert M; Bergmann R; Förster C; Sihver W; Vonhoff S; Klussmann S; Bethge L; Walther M; Schlesinger J; Pietzsch J; Steinbach J; Pietzsch HJ
Bioconjug Chem; 2017 Apr; 28(4):1176-1188. PubMed ID: 28222590
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors.
Vera DR; Eigner S; Beran M; Henke KE; Laznickova A; Laznicek M; Melichar F; Chinol M
Cancer Biother Radiopharm; 2011 Jun; 26(3):287-97. PubMed ID: 21711096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
